Pfizer Forecasts Roughly $15 Billion in Revenue for 2021 From COVID-19 Vaccine

Pfizer Inc. said they expect total revenue in sales of CCP virus vaccines in 2021 to generate roughly $15 billion.

Vials of coronavirus vaccine and a medical syringe are seen in front of a displayed Pfizer logo, on Oct. 31, 2020. Dado Ruvic/Reuters

Pfizer expects total revenue in sales of CCP virus vaccines it has developed with Germany’s BioNTech to generate roughly $15 billion in 2021.

The New York City-based drugmaker revealed the revenue projection in a statement on Tuesday, adding that the expectation primarily includes doses that are expected to be delivered this year under existing contracts, which may be subject to adjustments as additional contracts are added or removed.